4 Pharmaceutical Companies Leading the Breast Cancer Fight

By Lee Jackson Published May 8, 9:20AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

If one cancer strikes a chord with women all over the world, it is breast cancer. While treatments have improved dramatically, it still ranks as the most common cancer among women, with the exception of skin cancers. About one in eight (12%) women in the United States will develop invasive breast cancer during their lifetime. RBC analysts met with top physicians in Boston and hosted panels to find out what the best treatments currently are.

In a new report, the RBC team focused on the companies that are making the most progress with treatments for patients. We highlight four of them: Bristol-Myers Squibb Co. (NYSE: BMY), Merck & Co. Inc. (NYSE: MRK), Medivation Inc. (NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE).

Bristol-Myers Squibb

This company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules and biologics in various therapeutic areas, including virology, comprising human immunodeficiency virus infection (HIV), as well as oncology neuroscience immunoscience and cardiovascular.

Taxol (paclitaxel) is manufactured by Bristol-Myers Squibb and has long been used in the treatment of breast cancer and other cancers as well. The company also markets Ixempra (ixabepilone), which is a prescription medicine used to treat locally advanced or metastatic breast cancer when certain other medicines have not worked or no longer work. Ixempra can be used alone or with another cancer medicine called Xeloda (capecitabine).

ALSO READ: 5 Jefferies Franchise Pick Tech Stocks to Buy With Huge Upside

Bristol-Myers investors are paid a solid 2.3% dividend. The Thomson/First Call consensus price target for the stock is $70.13. Shares closed most recently at $65.05.

Merck

This stock has been hit hard since printing a high in late January. Although it has rallied back smartly, it still may be offering new investors a very good entry point. It also remains a leading health care company that is on the focus lists of many of the top firms we cover. The company’s numerous prescription medicines, vaccines, biologic therapies and consumer care and animal health products are provided to customers in more than 140 countries.

Merck is the world’s fourth-biggest drug maker by revenue. Merck said late last year its Keytruda shrank tumors to some extent in one-third of 27 patients evaluated in a study called Keynote-012. All had what is called triple-negative breast cancer that had spread outside the breast, and about 85% had worsened after multiple rounds of chemotherapy and other treatments — some five or more treatments. The company will be starting mid-stage patient tests of Keytruda soon. It has received accelerated approval for advanced melanoma but needs further testing for permanent approval.

Merck investors are paid a 3% dividend. The consensus price target is $65.34, and the stock closed Thursday at $60.30 a share.

ALSO READ: Fiber to the Premises Is Back: 4 Top Stocks to Buy Now

Medivation

This company is one that many Wall Street analysts are very bullish on as a possible buyout candidate. Medivation has a top prostate cancer drug that analysts feel would be a valuable acquisition. Xtandi is a highly leverageable likely blockbuster product in prostate cancer, a very large market segment, with potential upside in breast cancer. The company’s ongoing partnership with Astellas suggests a possible natural buyer, but other third parties looking to grow product sales would also be interested.

Medivation and Astellas announced late last year the presentation of Stage I and preliminary Stage II data from an open label, single-arm Phase 2 study (MDV3100-11) on Xtandi. The study is evaluating Xtandi as a single agent for the treatment of advanced androgen receptor positive triple negative breast cancer. The RBC specialists were not overly impressed with the results, but they did concede “There is some activity there, but clearly not a game changer.”

The consensus price target for the stock is $136.44. The stock ended trading on Thursday at $123.23 a share.

Pfizer

The company rocked Wall Street this year announcing a gigantic $15.2 billion purchase of Hospira. Hospira is a top provider of sterile injectable drugs, including those used for acute care and cancer treatment, infusion technologies and biosimilars, which are subsequent versions of drugs whose patents have expired. Recently, the company’s drug Ibrance was approved for advanced breast cancer by U.S. regulators more than two months ahead of schedule, letting the drug maker proceed with one of its most promising new blockbusters, a turn of events that Wall Street likes.

Pfizer investors are paid a solid 3.35% dividend. The consensus price target for the stock is posted at $37.13. Pfizer closed Thursday at $33.58.

ALSO READ: UBS Says to Buy the Big 3 Land Drillers Now

These companies are all top notch buys, especially the dividend-paying companies. With broad product lines and outstanding pipelines, they are outstanding long-term holds.

About the Author Lee Jackson →

Lee Jackson has covered Wall Street analysts' equity and debt research and equity strategy daily for 24/7 Wall St. since 2012. His broad and diverse career, which included a stint as the creative services director at the NBC affiliate in Austin, Texas, gives him unique insight into the financial industry and world.

Lee Jackson's journey in the financial industry spans over 30 years, with nearly two decades as an institutional equity salesperson at Bear Stearns, Lehman Brothers, and Morgan Stanley. His career was marked by his presence on the sell side during pivotal Wall Street events, from the dot.com rise and bubble to the Long Term Capital Management debacle, 9/11, and the Great Recession of 2008. This is a testament to his resilience and adaptability in the face of market volatility.

Lee Jackson’s practical financial industry experience, acquired from a career at some of the biggest banks and brokerage firms, is complemented by a lifetime of writing on various platforms. This unique combination allows him to shed light on the intricacies and workings of Wall Street in a way that only someone with deep insider experience and knowledge can. Moreover, his extensive network across Wall Street continues to provide direct access for him and 24/7 Wall St., a privilege few firms enjoy.

Since 2012, Jackson’s work for 24/7 Wall St. has been featured in Barron’s, Yahoo Finance, MarketWatch, Business Insider, TradingView, Real Money, The Street, Seeking Alpha, Benzinga, and other media outlets. He attended the prestigious Cranbrook Schools in Bloomfield Hills, Michigan, and has a degree in broadcasting from the Specs Howard School of Media Arts.